The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Full approval will depend on verification of clinical benefit in a confirmatory trial
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated
